The experience with elexacaftor/tezacaftor/ivacaftor + ivacaftor in adult patients with cystic fibrosis in the Omsk region

   Elexacaftor/tezacaftor/ivacaftor + ivacaftor, a drug modulating the cystic fibrosis transmembrane conductance regulator protein, is currently revolutionizing the management of patients with cystic fibrosis, particularly those with at least one F508del variant. CFTR modulators are characterized by individual pharmacokinetic variability and a tendency to drug-drug interactions, which accounts for their variable effects in different patients. This article reports the experience of using the targeted therapy of cystic fibrosis, elexacaftor/tezacaftor/ivacaftor + ivacaftor, for the treatment of adult patients with cystic fibrosis for a year.

   The aim was to study the efficacy and side effects of the drug elexacaftor/tezacaftor/ivacaftor + ivacaftor during 12 months of treatment of adult patients with cystic fibrosis in the Omsk region.

   Methods. The article presents the experience of using elexacaftor/tezacaftor/ivacaftor + ivacaftor for targeted therapy of adult patients with CF for 12 months.

   Results. The positive effect, good tolerability and safety of the combined drug elexacaftor/tezacaftor/ivacaftor + ivacaftor for the treatment of adult patients with CF were demonstrated.

   Conclusion. Timely initiation of targeted therapy for CF in childhood is likely to prevent the development of severe manifestations of the disease, but monitoring of patients with CF receiving targeted therapy should be continued.

1. Chuchalin A.G., ed. [Pulmonology. National leadership]. Moscow: GEOTAR-Media; 2018 (in Russian).

2. Union of Pediatricians of Russia. [Cystic fibrosis. Clinical guidelines]. 2021. Available at: https://mukoviscidoz.org/doc/%D0%9A%D0%A0372.pdf [Accessed: May 20, 2023] (in Russian).

3. Kosareva A.R., Bashkina O.A., Sergienko D.F. [Experience of using lumacaftor/ivacaftor in children with cystic fibrosis in the Astrakhan region]. Асtа Biomedica Scientifica. 2022; 7 (4): 101–108. DOI: 10.29413/ABS.2022-7.4.12 (in Russian).

4. Amelina E.L., Krasovskiy S.A., Usacheva M.V., Krylova N.A. [Pathogenic treatment of cystic fibrosis: the first clinical case in Russia]. Pul’monologiya. 2017; 27 (2): 298–301. DOI: 10.18093/0869-0189-2017-27-2-298-301 (in Russian).

5. Amelina E.L., Krasovskiy S.A., Shumkova G.L., Krylova N.A. [Тargeted therapy for CF patients with F508del/F508del genotype]. Pul’monologiya. 2019; 29 (6): 235–238. DOI: 10.18093/0869-0189-2019-29-2-235-238 (in Russian).

6. Kondratyeva E.I., Amelina E.L., Chernukha M.Yu. et al. [Review of clinical guidelines “Cystic fibrosis” (2020)]. Pul’monologiya. 2021; 31 (2): 135–146. DOI: 10.18093/0869-0189-2021-31-2-135-146 (in Russian).

7. Union of pediatricians of Russia. [Targeted therapy of cystic fibrosis (cystic fibrosis). Guidelines]. 2022. Available at: https://amg-genetics.ru/pdf/2022/kistozniy_fibroz_klin_rek_2022.pdf [Accessed: May 20, 2023] (in Russian).

8. DailyMed. Trikafta-elexacaftor, tezacaftor, and ivacaftor kit. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=-f354423a-85c2-41c3-a9db-0f3aee135d8d [Accessed: May 20, 2023].

9. Zaher A., ElSaygh J., Elsori D. et al. A review of trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus. 2021; 13 (7): e16144. DOI: 10.7759/cureus.16144.

10. National Library of Medicine. Tezacaftor. PubChem [Website]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Tezacaftor [Accessed: May 20, 2023].

11. Middleton P.G., Mall М.А., Dřevínek P. et al. Elexacaftortezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 2019; 381 (19): 1809–1819. DOI: 10.1056/NEJMoa1908639.

12. Moliteo E., Sciacca M., Palmeri A. et al. Cystic fibrosis and oxidative stress: the role of CFTR. Molecules. 2022; 27 (16): 5324. DOI: 10.3390/molecules27165324.

13. Choong E., Sauty A., Koutsokera A. et al. Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now? Pharmaceutics. 2022; 14 (8): 1674. DOI: 10.3390/pharmaceutics14081674.

14. Giallongo A., Parisi G.F., Papale M. et al. Effects of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory polygraphy parameters and respiratory muscle strength in cystic fibrosis patients with severe lung disease. Genes (Basel). 2023; 14 (2): 449. DOI: 10.3390/genes14020449.

15. Tsai A., Wu S.P., Haseltine E. et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor/tezacaftor/ivacaftor. Pulm. Ther. 2020; 6 (2): 275–286. DOI: 10.1007/s41030-020-00124-7.

16. Barry P.J., Mall M.A., Álvarez A. et al. Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes. N. Engl. J. Med. 2021; 385 (9): 815–825. DOI: 10.1056/NEJMoa2100665.

17. King J.A., Nichols A.L., Bentley S. et al. An update on CFTR modulators as new therapies for cystic fibrosis. Paediatr. Drugs. 2022; 24 (4): 321–333. DOI: 10.1007/s40272-022-00509-y